New situation in the battle of hepatitis C drugs: MSD abandons two drugs under research

Source: the development project of mk-3682b and mk-3682c for hepatitis C drugs was stopped by MSD on September 30, 2017 Will focus on zepatier ® (elbasvir / grazoprevir) The alarm goes on! Companies committed to the development of hepatitis C drugs, please think twice carefully! On September 29, 2017, MSD announced its strategic decision to terminate the development of mk-3682b (grazoprevir / ruzasvir / uprifosbuvir) and mk-3682c (ruzasvir / uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection The decision is based on a review of data on the effectiveness of existing phase 2 clinical trials and the growing number of drugs available for chronic HCV infection, taking into account the shrinking market These increasing drugs include zepatier (elbasvir and grazoprevir) developed by mosadon In the past few years, the battle of hepatitis C drugs has been extremely fierce! The dominant player in the field is gillid, followed by Alberto The cure rate of ji-1, ji-2, Ji-3 and other drugs can reach ~ 100%, which means that fewer and fewer patients will use drugs, and the drug market will gradually shrink, which in turn will further intensify competition Dr Eliav Barr, senior vice president, global clinical development of infectious diseases and vaccines, Merck Research Laboratories, said: "human beings have made remarkable progress in the fight against hepatitis C infection, and Merck is very proud of its role in this fight over the past 30 years We will continue to study zepatier to understand its role in the treatment of chronic hepatitis C, and will continue to work with other companies to use zepatier to help patients with genotype 1 and 4 hepatitis C, which account for the majority of patients with chronic hepatitis C " This is the latest in the hepatitis C war With such fierce competition, timely withdrawal is not necessarily the best policy!